Crossmark

Alpha-galactosylceramide pre-treatment attenuates clinical symptoms of LPS-induced acute neuroinflammation by converting pathogenic iNKT cells to anti-inflammatory iNKT10 cells in the brain

Crossref DOI link: https://doi.org/10.1007/s00011-024-01915-3

Published Online: 2024-07-19

Published Print: 2024-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Tae-Cheol

Park, Hyun Jung

Lee, Sung Won

Park, Yun Hoo

Van Kaer, Luc

Hong, Seokmann
Funding

Funding for this research was provided by:

National Research Foundation of Korea (NRF-2021R1I1A1A01051465, NRF-2021R1I1A1A01054418, NRF-2019R1A2C1009926)
License Information

Text and Data Mining valid from 2024-07-19

Version of Record valid from 2024-07-19
More Information

Article History

Received: 30 April 2024

Revised: 20 June 2024

Accepted: 3 July 2024

First Online: 19 July 2024

Declarations

:

: LVK is a scientific advisory board member of Isu Abxis Co., Ltd. (Republic of Korea). The other authors declare that the research was conducted without commercial or financial relationships that could be construed as a potential conflict of interest.

: The study was conducted according to the guidelines on the care and use of laboratory animals approved by the Institutional Animal Care and Use Committee of Sejong University (approved on 3 May 2022).

: Not applicable.

Document is current

Any future updates will be listed below